HomeCompareSTDE vs JNJ

STDE vs JNJ: Dividend Comparison 2026

STDE yields 2000000.00% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STDE wins by $4.879226400974806e+39M in total portfolio value
10 years
STDE
STDE
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full STDE calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — STDE vs JNJ

📍 STDE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTDEJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STDE + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STDE pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STDE
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, STDE beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STDE + JNJ for your $10,000?

STDE: 50%JNJ: 50%
100% JNJ50/50100% STDE
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

STDE
No analyst data
Altman Z
-57.7
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STDE buys
0
JNJ buys
0
No recent congressional trades found for STDE or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTDEJNJ
Forward yield2000000.00%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.879226400974806e+39M$30.5K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$4,749.88
Total dividends collected$4.879195005460081e+39M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: STDE vs JNJ ($10,000, DRIP)

YearSTDE PortfolioSTDE Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$200,010,700$200,000,000.00$10,594$274.49+$200.00MSTDE
2$3,738,731,768,458$3,738,517,757,009.35$11,294$360.69+$3738731.76MSTDE
3$65,315,062,866,930,490$65,311,062,423,938,240.00$12,133$476.91+$65315062866.92MSTDE
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$13,156$635.42+$1066400830062625.00MSTDE
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$14,432$854.61+$16272182796453826560.00MSTDE
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$16,056$1,162.76+$2.3205424011366188e+23MSTDE
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$18,175$1,604.53+$3.0927990661046884e+27MSTDE
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$21,009$2,252.68+$3.8524105697352695e+31MSTDE
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$24,911$3,229.73+$4.484688260147987e+35MSTDE
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$30,458$4,749.88+$4.879226400974806e+39MSTDE

STDE vs JNJ: Complete Analysis 2026

STDEStock

Standard Energy Corporation engages in the acquisition of unproven oil and gas leaseholds with the intent of reselling or drilling; and developing such leaseholds with third-parties. It acquires primarily federal oil and gas leaseholds. The company also obtains leases through purchases in competitive bidding programs offered by various state agencies, principally the states of Utah and Wyoming. Standard Energy Corporation retains a royalty interest, ranging from 1% to 6% in various leaseholds that it resells. The company, through its wholly owned subsidiary, Petroleum Investment Company, also offers various geologic lease evaluation services; and provides information relating to geologic data, recommendations, and reports with respect to leaseholds offered in the leasing programs. Standard Energy Corporation also sells information with respect to individual oil and gas properties throughout the Rocky Mountain area, as well as offers oil and gas mapping services about properties located in the Rocky Mountain region. Further, it engages in the commercial development of its 'Biofuel Technologies', which are designed to solve the problem of disposing of municipal solid waste, through the recycle of the 'paper waste' in municipal waste into useful products, such as ethanol transportation fuels and fermentation lignin turbine fuels. The company was founded in 1978 and is headquartered in Salt Lake City, Utah.

Full STDE Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this STDE vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STDE vs SCHDSTDE vs JEPISTDE vs OSTDE vs KOSTDE vs MAINSTDE vs ABBVSTDE vs MRKSTDE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.